Two dosage interferon-α2b maintenance therapy in patients affected by low-risk multiple myeloma in plateau phase: a randomized trial

MASSIMO OFFIDANI, ATTILIO OLIVIERI, MARCO MONTILLO, SERENA RUPOLI, RICCARDO CENTURIONI, FRANCESCO ALESIANI, GABRIELE MARCHEGIANI, STEFANO PIERONI, MASSIMO CATARINI, GENNARO PELLICCIA, FILIPPO ALTILIA, PIETRO LEONI

Clinica di Ematologia, Ancona University, Ospedale Torrette, Torrette di Ancona, Italy

ABSTRACT

**Background and Objective.** The role of interferon (IFN) in the remission phase of multiple myeloma (MM) is still an open question, particularly for its scheduling and the subset of patients who could benefit from this approach. The present randomized multicenter study was designed to compare two schedules of IFN maintenance therapy in order to assess the difference in effectiveness and tolerance.

**Design and Methods.** This prospective randomized multicenter study was attempted to assess the best schedule of IFN administration in the maintenance treatment of MM in plateau phase with regard to progression free survival (PFS) and toxicity. The second aim was defining the difference between the two schedules in overall survival (OS) and identifying the critical dose of IFN therapy needed to prolong plateau phase and survival. We enrolled 52 patients affected with low-risk MM (i.e. with serum β2-microglobulin < 6.0 mg/L and serum albumin > 3.0 g/dL); 27 patients (group A) were randomly assigned to receive IFN-α2b 3 megaunits (MU) subcutaneously three times a week and 25 patients (group B) 3 MU/day until disease progression.

**Results.** Median progression free survival (PFS) was 11.9 months in group A and 38.3 months in group B (p= 0.0038). Median survival was 63.2 months in group A and 61.9 months in group B (p= 0.489). However, those patients who were given an IFN dose ≥ 30 MU/month experienced a significantly longer PFS and survival than the other patients. Seventeen patients (32.7%) discontinued therapy and six patients (30.8%) reduced IFNα-2b dose because of severe side effects without having a significant difference between the two groups.

**Interpretation and Conclusions.** Our results show that patients treated with IFNα 3 MU/day had a significantly longer remission duration than patients treated with IFNα 3 MU three times weekly. Moreover, an IFN dose is probably critical for obtaining a longer survival in patients affected with low-risk MM. Since the patients’ discomfort during a IFN maintenance therapy was frequently experienced the quality of their lives should be carefully taken into account.

Although much progress has been made in the knowledge of biologic and prognostic factors of multiple myeloma (MM), survival has not significantly changed since the melphalan-prednisone combination was employed. Indeed, by introducing multidrug regimens, response rate has improved, but not survival. Interferon (IFN) used as single induction agent or in combination with conventional chemotherapy did not substantially change MM prognosis. High-dose therapy followed by allogeneic bone marrow transplantation was able to cure some patients, but can be performed only on a small group of patients; on the contrary, autologous stem cell transplantation can be widely performed and is now a standard procedure for treatment patients with MM although the relapse rate remains high.

Maintenance chemotherapy has not shown advantages in prolonging survival and a higher incidence of secondary leukemia was found. On the contrary, maintenance with IFN significantly prolonged response duration but not overall survival in patients who had responded to induction chemotherapy. Therefore the role of IFN in the remission phase of MM is still an open question, particularly for the schedule and the correct identification of the subset of patients who could benefit from this approach.

The present randomized multicenter study was designed to compare two schedules of IFN maintenance therapy in order to assess the difference in effectiveness and tolerance.

**Materials and Methods**

**Study design**

This prospective randomized multicenter study was attempted to assess the best schedule of IFN administration in the maintenance treatment of MM in plateau phase with regard to progression-free survival (PFS) and toxicity; the second aim was defining the difference between the two schedules in overall survival (OS) and identifying the critical dose of IFN therapy needed to prolong plateau...
phase and survival.

We enrolled patients affected by low-risk MM (see below) diagnosed according to Chronic Leukemia-Myeloma Task Force criteria, with the following characteristics: disease at any stage according to Durie and Salmon; no age limits; performance status (PS) < 2 according to World Health Organization (WHO); normal renal and hepatic function and no cardiac failure.

After oral informed consent, patients were randomly assigned to receive IFNα-2b (Intron-A, Schering-Plough Corp.) 3 megaunits (MU) three times a week (group A) or 3 MU/day (group B), subcutaneously, until disease progression occurred. IFNα-2b was administered on an outpatient basis and acetaminophen was used to reduce influenza-like symptoms at the discretion of the patients. Dose reduction was carried out according to WHO criteria; therapy discontinuation was provided only for grade III-IV WHO side effects, patient refusal or disease progression. However, the schedule (daily or intermittent administration) was maintained and the results were considered on an intention-to-treat basis for the primary end point.

Definition criteria

Low-risk MM was defined according to Bataille et al., staging system i.e. patients with serum β2-microglobulin < 6.0 mg/L and serum albumin > 3.0 mg/dL. Response to chemotherapy was assessed according to Chronic Leukemia-Myeloma Task Force criteria.

Plateau phase MM was defined as follows: persistent reduction or absence of MM symptoms, steadiness of hematological parameters without the need of transfusion and steadiness of paraprotein during a 3-month observation.

Disease progression was defined according to the following criteria: reappearance of MM symptoms; reappearance or increase of paraprotein greater than 50% or 100% in the serum or in the urine respectively; appearance or increase of lytic bone lesion; serum creatinine > 2.0 mg/dL; serum calcium > 12 mg/dL or appearance of plasmacells in the blood.

Side effects of IFNα-2b were evaluated according to WHO criteria. The planned dose of IFN was 36 MU/month for the group A and 72 MU/month for the group B. The cut-off dose of 30 MU/month is intended for at least 6 months.

PFS was calculated from time of randomization to disease progression and similarly OS was calculated from randomization to death for any events.

Follow-up

Before randomization and every two months thereafter, patients underwent clinical and laboratory examinations including hemocytometric counts, electrophoresis serum and 24-hour urine samples for paraprotein determination, renal and hepatic functions, serum calcium and sβ2m. Every 12 months or when clinically indicated, a bone marrow biopsy and a complete skeletal radiography were performed.

Once disease progression was established during the IFN therapy, subsequent chemotherapy was left at the discretion of the attending physicians. One patient (group A) underwent myeloablative therapy followed by blood progenitor cell rescue; all the other patients were treated with conventional chemotherapy including oral melphalan-prednisone, VMCP, VBMCP, VAD, high-dose dexamethasone or cyclophosphamide regimens. No randomized patient was lost to follow-up.

Statistical methods

The sample size of the population was calculated to ensure a 5% level of significance and a power of 80% if a difference in the probability of PFS was 35% between the two schedules of IFN administration. Randomization was made centrally by using a standard computer program.

The characteristics of the two groups of patients as well as toxicity were compared by using the Mann-Whitney test for continuous variables and chi-square test (contingency table) for categorical variables.

PFS and OS estimate were performed by Kaplan-Meier method and compared by using log-rank test. The best cut-off of dose of IFN therapy was empirically pursued using log-rank test to compare the Kaplan-Meier curves of PFS and OS. In order to weight its prognostic value, IFN dose was included in a stepwise Cox regression analysis together with age, PS (0-1 vs 2), stage (I vs II-III), serum β2-microglobulin, serum albumin and bone marrow plasmacells. A p value < 0.05 was considered statistically significant.

Results

Patient population

From January 1989 to December 1994, 196 untreated patients affected by MM were reported in 10 medical departments of the Marche region (Italy). One hundred two patients (52%) were affected by low-risk MM according to the Bataille et al., staging system. Five of these patients (4.9%) were excluded because of important concomitant diseases. Twenty patients (19.6%) had stable MM stage I A; since they were not suitable for treatment and were excluded. The remaining 77 patients (75.5%) were available for treatment but 3 of them refused the protocol, 2 died before randomization and 3 others were lost at follow-up. Out of the remaining 69 patients treated, 52 responded to chemotherapy and therefore were randomized for the two different dose of IFN.
ized patients, 44 (22 group A, 22 group B) received oral melphalan plus prednisone for seven days,\textsuperscript{25,26} and 4 (2 group A, 2 group B) VBMCP regimen\textsuperscript{26} and 4 (3 group A, 1 group B) were treated with VAD regimen.\textsuperscript{27}

Clinical and laboratory characteristics of the 52 randomized patients are listed in Table 1. Twenty-seven patients were randomly assigned to group A (IFN\textsubscript{3} MU three times a week) and 25 to group B (3 MU/day). As shown in Table 1, the two groups were comparable for all the considered characteristics.

**Progression-free survival**

Up to December 1996, with a median follow-up time of 42 months, 31 patients (59.6%) experienced disease progression, 21 (77.8%) in group A and 10 (40.0%) in group B (p = 0.01273). The total median PFS was 24.8 months; in group A the median PFS was 11.9 months and 38.3 months in group B (p = 0.0038) (Figure 1).

PFS of 37 patients given a dose of IFN $\geq 30$ MU/month was 34.3 months vs 10.4 months of the 15 patients treated with a lower dose (p = 0.0015; Figure 2).

**Overall survival**

Eighteen patients (34.6%) died by the time of this report, 11 (40.7%) in group A and 7 (28%) in group B (p = 0.50084). All patients in group A died

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
<th>Group A\textsuperscript{*}</th>
<th>Group B\textsuperscript{°}</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>52</td>
<td>27</td>
<td>25</td>
<td>/</td>
</tr>
<tr>
<td>Age</td>
<td>67.5 (47-85)</td>
<td>66 (51-83)</td>
<td>70 (47-85)</td>
<td>0.117</td>
</tr>
<tr>
<td>Sex</td>
<td>M 24</td>
<td>13</td>
<td>11</td>
<td>0.983</td>
</tr>
<tr>
<td></td>
<td>F 28</td>
<td>14</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Paraprotein</td>
<td>IgG 37</td>
<td>20</td>
<td>17</td>
<td>0.393</td>
</tr>
<tr>
<td></td>
<td>IgA 9</td>
<td>3</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bence-Jones 6</td>
<td>4</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td>I 23</td>
<td>12</td>
<td>11</td>
<td>0.945</td>
</tr>
<tr>
<td></td>
<td>II-III 2</td>
<td>15</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>PS (WHO)</td>
<td>0-1 28</td>
<td>14</td>
<td>14</td>
<td>0.983</td>
</tr>
<tr>
<td></td>
<td>2 24</td>
<td>13</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Bone marrow plasma cells (%) – median (range)</td>
<td>41.5 (15-90)</td>
<td>40 (20-83)</td>
<td>49 (15-90)</td>
<td>0.2051</td>
</tr>
<tr>
<td>$\beta$2 microglobulin (mg/mL) – median (range)</td>
<td>2.4 (1.2-4.8)</td>
<td>2.5 (1.2-4.8)</td>
<td>2.3 (1.3-4.5)</td>
<td>0.486</td>
</tr>
<tr>
<td>Albumin (g/mL) – median (range)</td>
<td>4.0 (3.0-5.1)</td>
<td>4.3 (3.0-5.1)</td>
<td>3.8 (3.0-5.0)</td>
<td>0.748</td>
</tr>
<tr>
<td>Hemoglobin (g/dL) – median (range)</td>
<td>12.4 (8.6-17.0)</td>
<td>13.0 (8.6-17.0)</td>
<td>12.1 (8.9-16.9)</td>
<td>0.230</td>
</tr>
<tr>
<td>Platelets (x10\textsuperscript{9}/L) – median (range)</td>
<td>195 (69-389)</td>
<td>200 (69-329)</td>
<td>190 (96-389)</td>
<td>0.647</td>
</tr>
<tr>
<td>LDH (U/L) – median (range)</td>
<td>238 (125-440)</td>
<td>230 (130-430)</td>
<td>250 (125-440)</td>
<td>0.287</td>
</tr>
</tbody>
</table>

\textsuperscript{*}IFN 3 MU three times a week; \textsuperscript{°}IFN 3 MU/day.

---

Figure 1. Kaplan-Meier progression free survival (PFS) curves according to the IFN schedule. Patients treated with IFN 3 MU/die had a significantly longer PFS than patients treated with IFN 3 MU three times a week (median PFS 38.3 vs 11.9 months; p = 0.0038).
Interferon maintenance in patients with low-risk multiple myeloma

because of disease progression; on the contrary, in group B, 3 patients died on stable disease (2 cerebral hemorrhages with normal platelet count and 1 cardiac failure).

Total median duration of survival was 63.5 months; in group A survival was 63.2 months and 61.9 months in group B (p = 0.489) (Figure 3). Even if we censored the patients who died on stable disease for causes apparently unrelated to MM, survival was not significantly different between the two groups (p = 0.1126: data not shown). However, comparing those patients given a dose of IFN ≥ 30 MU/month with those treated with a lower dose, the median survival proved to be significantly different (71.0 vs 46.5 months respectively; p = 0.0043; Figure 4).

Prognostic factors

Stepwise Cox regression analysis showed that only serum β2-microglobulin and IFN dose affected PFS (Table 2); whereas age, PS (WHO), stage, serum albumin and bone marrow plasmacells did not.

 Patients given a dose of IFN < 30 MU/month had a 60% higher probability of disease progression than patients treated with the higher dose of IFN ≥ 30 MU/month (Table 2).

Stepwise Cox regression analysis showed that not only serum β2-microglobulin and age were significantly predictive for longer OS but also IFN dose (Table 2). Indeed, patients given a dose of IFN < 30 MU/month had quite a double risk of death than patients treated with a dose of IFN ≥ 30 MU/month (Table 2).

Toxicity

Fourty-three patients (82.7%) experienced side effects without any difference between the two groups (Table 3). Side effects are shown in detail in Figure 5. Thirty-seven patients (71.2%) received a IFN dose ≥ 30 MU/month; however, 10 patients in group A (37%) and 5 patients in group B (20%) received a IFN dose less than 30 MU/month (Table 3). Sixteen patients (30.8%) reduced the dose of IFNα-2b because of side effects without any difference between the two schedules. The median age of patients who needed reduction of dose was 69 years vs 66 years for patients who did not (p = 0.5718). The main causes of therapy reduction were grade III neutropenia (9 patients), anorexia (4 patients) and fatigue (3 patients).

Seventeen patients (32.7%) discontinued therapy
because of severe side effects without any difference between the two schedules; among these, 13 patients had previously reduced IFN dosage. The median age of patients discontinuing therapy was 73 years compared to 66 years for patients not discontinuing (p= 0.05). The more frequent causes of therapy interruption were anorexia with weight loss (6 patients), toxic neurological effects (4 patients), ischemic heart attack (3 patients), itching (3 patients) and neutropenia (3 patients).

### Table 2. Prognostic factors for PFS and overall survival selected by stepwise Cox regression.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients at risk</th>
<th>p value</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Progression-free survival</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β2 microglobulin ≤ 3 mg/L</td>
<td>30</td>
<td>&lt; 0.001</td>
<td>3.3 (2.2-5.5)</td>
</tr>
<tr>
<td>&gt; 3 mg/L</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN dose &lt; 30 MU/month</td>
<td>15</td>
<td>0.0054</td>
<td>1.6 (1.2-2.4)</td>
</tr>
<tr>
<td>≥ 30 MU/month</td>
<td>37</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Overall survival** |                |         |                        |
| β2 microglobulin ≤ 3 mg/L | 30 | 0.017 | 2.3 (1.4-3.9) |
| > 3 mg/L | 22 |         |                        |
| Age > 65 years | 32 | 0.0260 | 1.1 (1.1-1.2) |
| ≤ 65 years | 20 |         |                        |
| IFN dose < 30 MU/month | 15 | 0.0230 | 1.9 (1.1-3.3) |
| ≥ 30 MU/month | 37 |         |                        |

*confidence interval.

### Table 3. Toxicity of the two schedules of IFNα and comparison.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Total pts (%)</th>
<th>Group A pts (%)</th>
<th>Group B pts (%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Side effects</td>
<td>43 (82.7)</td>
<td>22 (81.5)</td>
<td>21 (84.0)</td>
<td>0.932</td>
</tr>
<tr>
<td>Dose reduction</td>
<td>16 (30.8)</td>
<td>7 (25.9)</td>
<td>9 (36.0)</td>
<td>0.843</td>
</tr>
<tr>
<td>Therapy discontinuation</td>
<td>17 (32.7)</td>
<td>9 (33.3)</td>
<td>8 (32.0)</td>
<td>0.932</td>
</tr>
<tr>
<td>Therapy reduction then discontinuation</td>
<td>13 (25.0)</td>
<td>7 (25.9)</td>
<td>6 (24.0)</td>
<td>0.832</td>
</tr>
<tr>
<td>IFN dose &lt; 30 MU/month</td>
<td>15 (28.8)</td>
<td>10 (37.0)</td>
<td>5 (20.0)</td>
<td>0.462</td>
</tr>
</tbody>
</table>

*IFN 3 MU three times a week; °IFN 3 MU/day. Pts: patients.

### Discussion

Interferon is a biological response modifier which is able to carry on a direct and indirect antimyeloma activity in vitro. In patients with MM responding to conventional chemotherapy, IFNα maintenance treatment has given conflicting results. Indeed some authors obtained a duration of plateau phase significantly longer in IFN treated groups than in unmaintained ones, on the contrary, in other trials no difference in the length of plateau phase between IFN treated groups and control groups was observed. However, survival of the patients treated with IFN was not improved in all the above trials. IFN combined with induction chemotherapy and for maintenance treatment gave disappointing results.

![Figure 5. Side effects according the IFN schedule (group B: IFN 3 MU/day; group A: IFN 3 MU three times a week).](image-url)
except in one study where only IgA and Bence-Jones myeloma patients had a significantly higher rate of remission and longer survival and in another where the same results were obtained in all patients.41

Better results have been obtained when tumor size, measured by paraprotein level, was minimal.17,33 However, the paraprotein level may not be the most accurate measure of tumor size and accordingly, it should not be considered the most important prognostic factor.22,42 Moreover, in the plateau phase the kinetic of myeloma cells is rather variable regardless of the paraprotein level.43

In vitro and in vivo IFN effects on myeloma cells are unclear; indeed, in vitro studies showed that IFN stimulated the proliferation of IL-6-dependent myeloma cell lines44,45 and of freshly explanted myeloma cells in a significant fraction of patients.46-48 Klein et al. demonstrated that, in vitro, low dose IFN inhibited myeloma cell growth while a high-dose inhibited plasma cell proliferation. These observations might explain the different results obtained in the above-mentioned trials and would suggest further investigations about factors which more carefully predict plateau phase and survival duration.

We supposed that patients with low-risk MM according to Bataille et al.22 were suitable to be treated with IFNα. In this setting we hoped to obtain a long-drawn plateau phase with low-dose IFNα. Indeed, all our patients had low tumor burden; moreover, they were responsive to chemotherapy. It has been demonstrated that patients with low tumor burden and/or responsive to chemotherapy maintained an intact NK activity, which can be enhanced by IFNα.49

Our results demonstrated that patients treated with IFNα 3 MU/day had a remission duration significantly longer than patients treated with IFNα 3 MU three times weekly. In spite of the considerable difference in the plateau phase duration, survival was not differentiated in the two randomized groups. This result, even if already described by others16-19,33-35,50 is surprising and indicates that much more effort should be made to explain this issue.

For this purpose we investigated the role of dosage of IFN maintenance therapy. Our findings showed that patients given a low dose of IFN (e.g. < 30 MU/month) experienced a significantly shorter survival than patients treated with a higher dose; moreover, the latter group of patients obtained a by far longer survival (71 months) than expected (55 months) in the low-risk MM.22 Many patients (37%) enrolled in schedule A (i.e. IFN 3 MU three times weekly) were not given a sufficient dose of IFN since even a small dose reduction was enough to take down IFN dose under the 30 MU/month (planned dose 36 MU/month); on the contrary, in the B arm (i.e. IFN 3 MU/die), a halved dose was also higher than 30 MU/month (planned dose 72 MU/month).

Regardless on this, a 20% of patients treated with schedule B received a IFN dose less than 30 MU/month. We can argue that this high percentage of patients, randomized in the B arm and treated with an insufficient dose of IFN, was responsible for the overlapping in the survival between the two schedules.

It is probable that the dose of IFN may have a heavier weight on OS than the administration schedule; however, IFN therapy could distinguish between patients who can tolerate a higher dose and therefore in a better condition, and who have a better prognosis than those who cannot. This dilemma should be solved by an appropriately designed randomized study.

The toxicity of IFNα was not negligible in both arms without any difference; our results suggest that, in patients affected by MM, a low dose of IFN also give rise to a considerable hematological and extrahematological toxicity; this did not happen in other hematological diseases (i.e. chronic myeloproliferative syndromes) where the IFN compliance is fulfilled for high doses also. This phenomenon can be probably attributed to the advanced age of patients with MM. Indeed, Westin et al. also reported severe granulocytopenia in about 25% of patients and chronic fatigue syndrome in about 20% of patients and consequently, the planned dose of 5 MU three times weekly was reduced in many patients. Moreover, Cunningham et al. reported therapy discontinuation in about 30% of MM patients maintained with IFN 3 MU three times weekly after autologous transplantation. Therefore, it is evident that IFN, even if at low dose, is not well tolerated in patients affected by MM.

In conclusion, this study suggests that the IFN dose in the maintenance therapy of MM is important in order to obtain a longer plateau phase duration; moreover, a critical dose of IFN is probably needed to also obtain a longer survival than expected in patients affected with low-risk MM.22 Since the toxicity of the two tested schedules is quite similar, we recommend the schedule that contains the higher dose of IFN enabling the administration of a sufficient dose regardless of dose reduction or therapy discontinuation.

Further studies are needed to investigate the role of IFN dose during survival also in other subsets of MM patients.51 Indeed, this issue is crucial to assess the cost-benefit ratio of IFN maintenance therapy in patients affected by MM whose quality of life could worsen with this therapy.52

Contributions and Acknowledgments

M. Offidani: conception and design, patient recruitment and randomization, data handling, day-to-day contact with participants, statistical analysis, data interpretation and writing of the paper.

A. Olivieri: conception, design and writing the study proto-
col, data interpretation and revising the paper. P. Leoni: conception, design, revising the paper and approval the final version to be published. M. Montillo, S. Rupoli, R. Centurioni, F. Alesiani, G. Marchegiani, S. Pieroni, M. Catarini, G. Pelliccia, F. Altilla: clinical assessment, execution of the study. The criteria of the order in which the above names appear are based on the decreasing importance of contribution to the paper except for P. Leoni, who is responsible of the final version of this paper.

We wish to thank Dr. Marino Brunori for his references research.

**Funding**
This work was partially supported by grants from AIL (Associazione Italiana contro le Leucemie) and from MURST-60%.

**Disclosures**
Conflict of interest: none.
Redundant publications: no overlapping with previous paper.

**Manuscript processing**
Manuscript received August 20, 1997; accepted October 15, 1997.

**References**

29. Einhorn S, Fernberg JO, Grandé Dr, Lewenson R. Interferon exerts a cytotoxic effect on primary human...
Interferon maintenance in patients with low-risk multiple myeloma


